Intelligroup
Successfully Completes Oracle 11i
Implementation at Telik Global Delivery
Model, Compliance and Validation Know-How,
Keys to Success
Edison, NJ (October 11, 2005)
Intelligroup Inc., a global provider
of strategic consulting services and
partner to some of the world’s
largest companies today announced
the completion of Oracle 11i e-Business
Suite implementation for Telik, a
biopharmaceutical company dedicated
to discovering, developing and commercializing
novel small molecule drugs to treat
cancer. Intelligroup’s demonstrated
domain knowledge and Life Sciences
expertise were essential to delivering
a fully validated and compliant ERP
system in just five months.
Using Oracle’s
Application Implementation Methodology
to guide the process, the Intelligroup
team implemented modules for Financial
Accounting, including SOX for Internal
Controls, Supply Chain and Quality
Process. Additionally, using industry
best practices with adherence to Telik’s
Corporate Quality Assurance standards
and GMP/FDA guidelines, Intelligroup
validated the implementation to ensure
regulatory compliance.
“Meeting our
timeline for implementation and validation
was critical to Telik attaining its
strategic business objectives,”
said Wendy Wee, VP and Controller
of Telik. “Intelligroup’s
knowledge of both Oracle and thecompliance/validation
issues helped Telik meet its timeline
and provided the quality consulting
services promised.”
“Intelligroup
is very pleased to add Telik to our
long list of satisfied customers,”
said Sivakumar Rajagopalan, Vice President
of Intelligroup’s Life Science
Practice. “It is always gratifying
to work with clients to improve efficiencies
and provide services that enable business
process improvements to meet organizational
objectives.”
“Intelligroup’s
proven Global Delivery Model, extensive
vertical knowledge, and expertise
in Oracle Process Manufacturing and
Financials were instrumental in bringing
this project to a successful conclusion
– on time and within budget,”
said Srinivas BK, Associate Director,
Oracle Practice.
About Telik
Telik, Inc. of Palo Alto,
CA is a biopharmaceutical company
focused on discovering, developing
and commercializing novel small molecule
drugs to treat cancer. The company’s
most advanced drug development candidate
is TELCYTA™ (TLK286), a tumor-activated
small molecule product candidate.
TELCYTA is in three Phase 3 registration
trials in advanced ovarian and non-small
cell lung cancer. A second drug development
candidate, TELINTRA™ (TLK199),
is in Phase 2 clinical development
in myelodysplastic syndrome. Telik’s
product candidates were discovered
using its proprietary drug discovery
technology, TRAP, which enables the
rapid and efficient discovery of small
molecule drug candidates. Additional
information is available at www.telik.com
About Intelligroup
Intelligroup is a strategic partner
to the world’s largest companies.
Its proven onsite/offshore delivery
model has enabled hundreds of customers
to accelerate results and reduce costs
up to 50%. With deep expertise in
industry-specific enterprise solutions,
Intelligroup has earned a reputation
for consistently exceeding client
expectations. Intelligroup develops,
implements and supports IT solutions
for some of the largest U.S. school
systems and global corporations including
GE, Hershey, Abbott Labs, Eastman
Chemical, Hitachi, and Kimball International.
Trademarks
Oracle, JD Edwards, and PeopleSoft
are registered trademarks of Oracle
Corporation and/or its affiliates.
|
